Method of eradicating ticks that attach to humans using lotilaner formulations
Inventors
Azamian, Bobak Robert • Ackermann, Douglas Michael • Stivers, Christopher • Hickok, Shawn D.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12502377-B2
Publication Date
2025-12-23
Expiration Date
Abstract
Disclosed herein are methods of eradicating ticks that attach to a human subject, thereby preventing potential transmission of vector-borne diseases including Lyme disease, via delivery of one, two, or more systemic doses of a lotilaner anti-parasitic therapeutic agent to the subject.
Core Innovation
The partial content describes a method of administering lotilaner orally to humans to kill ticks that attach to the human. It also describes reducing transmission of tick-borne disease through tick killing and identifies lotilaner as an isoxazoline parasiticide. The supplied material presents initial and follow-up dosing approaches, including recurring dosing, without providing the full abstract or summary text.
The background section is not included in the partial content, so the problem being solved as stated in that section is not explicitly described in patent. The supplied summary also refers to wider vector-borne disease applications but does not provide further detail on those applications. The claim text focuses specifically on killing ticks that attach to a human.
Claims Coverage
The two independent claims cover two inventive features concerning oral administration of lotilaner to kill ticks that attach to a human.
Two-dose oral lotilaner treatment
The claim covers administering a first oral dose of a composition comprising lotilaner to a human, followed by a second oral dose. The doses are administered at separate time points as part of a method of killing ticks that attach to the human. Specific dose amounts and timing are omitted.
Initial and follow-up oral lotilaner treatment
The claim covers orally administering a lotilaner composition to a human at an initial time point and administering one or more lower-amount lotilaner compositions at additional time points, as a method of killing ticks that attach to the human. Specific dose amounts and timing are omitted.
The independent claims cover oral lotilaner treatment of humans to kill attached ticks, using either a two-dose approach or an initial dose followed by lower-amount additional doses.
Stated Advantages
Kills ticks that attach to a human.
Reduces or prevents transmission of tick-borne disease through tick killing.
Documented Applications
Treatment of humans to kill attached ticks.
Prevention of tick-borne disease transmission through tick killing.
The partial content refers to wider vector-borne disease prevention applications but does not specify them further.
Interested in licensing this patent?